POAG
MCID: GLC092
MIFTS: 58

Glaucoma, Primary Open Angle (POAG)

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Glaucoma, Primary Open Angle

MalaCards integrated aliases for Glaucoma, Primary Open Angle:

Name: Glaucoma, Primary Open Angle 57 75 38 73
Primary Open Angle Glaucoma 38 12 37 29 55 6 15
Glaucoma 1, Open Angle, E 57 75 29 13 6 73
Poag 57 75
Adult-Onset Primary Open Angle Glaucoma 75
Glaucoma, Open Angle, Primary ) 40
Primary Open Angle Glaucoma 1e 75
Chronic Simple Glaucoma 12
Glc1e 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
glaucoma, primary open angle:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 137760
Disease Ontology 12 DOID:1070
ICD10 33 H40.11 H40.1
ICD9CM 35 365.11
MeSH 44 D005902
NCIt 50 C35394
SNOMED-CT 68 77075001
KEGG 37 H00612
SNOMED-CT via HPO 69 263681008 57190000 392288006

Summaries for Glaucoma, Primary Open Angle

UniProtKB/Swiss-Prot : 75 Glaucoma 1, open angle, E: A form of primary open angle glaucoma (POAG). POAG is characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. Glaucoma, primary open angle: A complex and genetically heterogeneous ocular disorder characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. In some cases, POAG shows digenic inheritance involving mutations in CYP1B1 and MYOC genes.

MalaCards based summary : Glaucoma, Primary Open Angle, also known as primary open angle glaucoma, is related to glaucoma 3, primary congenital, a and glaucoma 1, open angle, a. An important gene associated with Glaucoma, Primary Open Angle is OPTN (Optineurin), and among its related pathways/superpathways are Ribosome biogenesis in eukaryotes and Elastic fibre formation. The drugs Travoprost and Latanoprost have been mentioned in the context of this disorder. Affiliated tissues include Eye, eye and testes, and related phenotypes are myopia and open angle glaucoma

OMIM : 57 Quigley (1993) reviewed adult-onset primary open angle glaucoma, which combines a particular abnormal appearance of the optic disc (optic nerve head) with a slowly progressive loss of visual sensitivity. Many patients with glaucoma have intraocular pressures above the normal range, although this cannot be considered part of the definition of the disease, since some patients have normal intraocular pressures. Changes in the optic disc, either inherited or acquired, contribute to the development of the disorder, which leads to visual loss from increasing nerve fiber layer atrophy. Quigley et al. (1994) stated that POAG should be reviewed as a multifactorial disorder. (137760)

Related Diseases for Glaucoma, Primary Open Angle

Diseases in the Open-Angle Glaucoma family:

Glaucoma 1, Open Angle, a Glaucoma, Primary Open Angle
Glaucoma 1, Open Angle, P Glaucoma 1, Open Angle, I

Diseases related to Glaucoma, Primary Open Angle via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 glaucoma 3, primary congenital, a 32.9 OPTN MYOC CYP1B1
2 glaucoma 1, open angle, a 32.8 OPTN MYOC CYP1B1
3 adamantinoma of long bones 31.6 WDR36 OPTN MYOC GSTM1 CYP1B1 CDKN2B-AS1
4 primary angle-closure glaucoma 31.4 OPTN MYOC CYP1B1
5 open-angle glaucoma 31.1 WDR36 TMCO1 TGFB2 SIX6 OPTN MYOC
6 optic nerve disease 30.9 UBL4A OPTN MYOC
7 ocular hypertension 30.8 TMCO1 OPTN MYOC
8 primary congenital glaucoma 30.5 WDR36 OPTN MYOC CYP1B1
9 chronic closed-angle glaucoma 30.4 TGFB2 OPTN
10 glaucoma, normal tension 30.3 OPTN LOXL1
11 neovascular glaucoma 30.2 TGFB2 OPTN
12 low tension glaucoma 30.0 WDR36 OPTN MYOC GAS7 CDKN2B-AS1 ATOH7
13 juvenile glaucoma 29.9 WDR36 UBL4A TGFB2 OPTN MYOC ELN
14 glaucoma 1, open angle, f 11.7
15 glaucoma 1, open angle, j 11.7
16 glaucoma 1, open angle, d 11.6
17 glaucoma 1, open angle, k 11.6
18 glaucoma 1, primary open angle, c 11.5
19 glaucoma 1, open angle, p 11.3
20 glaucoma 1, open angle, g 11.2
21 glaucoma 1, open angle, o 11.2
22 myopia 10.6
23 neuropathy 10.4
24 helicobacter pylori infection 10.4
25 macular degeneration, age-related, 1 10.3
26 acrofrontofacionasal dysostosis 10.3 OPTN CYP1B1
27 glaucoma-related pigment dispersion syndrome 10.3 LOXL1 CYP1B1
28 hydrophthalmos 10.3 OPTN CYP1B1
29 macular retinal edema 10.3
30 excessive tearing 10.3 OPTN MYOC CYP1B1
31 corneal edema 10.3 OPTN MYOC CYP1B1
32 autosomal recessive cutis laxa type iii 10.2 OPTN ELN
33 early-onset glaucoma 10.2 MYOC CYP1B1
34 axenfeld-rieger syndrome, type 2 10.2 OPTN ASB10
35 phacogenic glaucoma 10.2 OPTN LOXL1 ELN
36 axenfeld-rieger syndrome 10.2 OPTN CYP1B1 ASB10
37 phimosis 10.2 ELN CYP1B1
38 alzheimer disease 10.2
39 diabetes mellitus 10.2
40 dementia 10.2
41 coloboma of macula 10.2 OPTN CYP1B1 ATOH7
42 aortic aneurysm 10.2 TGFB2 ELN CDKN2B-AS1
43 iris disease 10.1 OPTN LOXL1
44 aging 10.1
45 kearns-sayre syndrome 10.1
46 glaucoma 3, primary infantile, b 10.1
47 yemenite deaf-blind hypopigmentation syndrome 10.1
48 anxiety 10.1
49 ischemic optic neuropathy 10.1
50 retinal vein occlusion 10.1

Comorbidity relations with Glaucoma, Primary Open Angle via Phenotypic Disease Network (PDN):


Chronic Closed-Angle Glaucoma Hypertension, Essential
Ocular Hypertension Ocular Hypotension
Open-Angle Glaucoma Residual Stage of Open Angle Glaucoma

Graphical network of the top 20 diseases related to Glaucoma, Primary Open Angle:



Diseases related to Glaucoma, Primary Open Angle

Symptoms & Phenotypes for Glaucoma, Primary Open Angle

Symptoms via clinical synopsis from OMIM:

57
Eyes:
myopia
open angle glaucoma

Misc:
more frequent among african americans


Clinical features from OMIM:

137760

Human phenotypes related to Glaucoma, Primary Open Angle:

32
# Description HPO Frequency HPO Source Accession
1 myopia 32 HP:0000545
2 open angle glaucoma 32 HP:0012108

GenomeRNAi Phenotypes related to Glaucoma, Primary Open Angle according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.02 COCH MYOC OPTN SIX6 UBL4A

Drugs & Therapeutics for Glaucoma, Primary Open Angle

Drugs for Glaucoma, Primary Open Angle (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Travoprost Approved Phase 4,Phase 3,Phase 2,Not Applicable 157283-68-6 5282226
2
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130209-82-4 5311221 5282380
3
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 155206-00-1 5311027
4
Ketorolac Approved Phase 4,Not Applicable 66635-83-4, 74103-06-3 3826
5
Timolol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 26839-75-8 33624 5478
6
Brinzolamide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 138890-62-7 68844
7
Dorzolamide Approved Phase 4,Phase 3,Phase 2,Not Applicable 120279-96-1 5284549 3154
8
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
10
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
12
Pilocarpine Approved, Investigational Phase 4,Not Applicable 54-71-7, 92-13-7 5910
13
Maleic acid Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 110-16-7 444266
14 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Ketorolac Tromethamine Phase 4,Not Applicable
18 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Carbonic Anhydrase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Adrenergic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 Adrenergic Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Not Applicable
25 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Not Applicable
26 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Not Applicable
27 Brimonidine Tartrate Phase 4,Phase 3,Phase 2,Not Applicable 70359-46-5
28 Mitomycins Phase 4,Phase 2,Phase 1,Not Applicable
29 Anesthetics Phase 4,Phase 1,Phase 2,Not Applicable
30 Anti-Bacterial Agents Phase 4,Phase 2,Not Applicable
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Antibiotics, Antitubercular Phase 4,Phase 2,Not Applicable
33 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Anti-Infective Agents, Local Phase 4
35 Benzalkonium Compounds Phase 4
36 Anti-Infective Agents Phase 4,Not Applicable
37 Brimonidine Tartrate, Timolol Maleate Drug Combination Phase 4,Phase 3,Not Applicable
38 Anticoagulants Phase 4
39 Dextrans Phase 4
40 Blood Substitutes Phase 4
41 Cloprostenol Phase 4,Phase 3
42 Plasma Substitutes Phase 4
43 Luteolytic Agents Phase 4,Phase 3
44 Contraceptive Agents Phase 4,Phase 3
45 Lubricant Eye Drops Phase 4,Phase 3,Phase 2,Not Applicable
46 Polymyxins Phase 4
47
protease inhibitors Phase 4
48 HIV Protease Inhibitors Phase 4
49 Antineoplastic Agents, Hormonal Phase 4,Not Applicable
50 glucocorticoids Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 341)
# Name Status NCT ID Phase Drugs
1 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
2 Evaluation of the XEN Implant in Moderate POAG Subjects Unknown status NCT02006693 Phase 4
3 Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
4 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Unknown status NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
5 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
6 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
7 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
8 Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
9 A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma Completed NCT00911924 Phase 4
10 Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG) Completed NCT00913029 Phase 4 latanoprost/timolol
11 Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension Terminated NCT02047630 Phase 4 Generic latanoprost;Brand-name latanoprost
12 Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost Completed NCT03331770 Phase 4 Latanoprost Ophthalmic Product
13 Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00966940 Phase 4 Travoprost 0.004% ophthalmic solution (TRAVATAN);Tafluprost 0.0015% ophthalmic solution
14 Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00372827 Phase 4 Brinzolamide 1% added to Travoprost 0.004%
15 Efficacy And Safety of Pneumatic Trabeculoplasty Completed NCT01540331 Phase 4
16 A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent Active, not recruiting NCT01252914 Phase 4
17 Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) Completed NCT02863705 Phase 4 brimonidine tartrate/timolol malate Ophthalmic Solution;bimatoprost ophthalmic solution 0.01%
18 Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension Terminated NCT00471068 Phase 4 Travatan;Cosopt;Placebo (Timolol Vehicle)
19 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
20 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination Completed NCT00972257 Phase 4 treatment with dorzolamide/timolol;treatment with brimonidine/timolol
21 A Study of LUMIGAN® RC in the Clinical Setting Completed NCT01833741 Phase 4 Bimatoprost 0.01%
22 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02020512 Phase 4 0.03% Bimatoprost
23 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02003534 Phase 4 0.15% Brimonidine Tartrate
24 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02061683 Phase 4 Bimatoprost 0.03%
25 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
26 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
27 Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStents Completed NCT01252888 Phase 4
28 Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents Completed NCT01252862 Phase 4
29 Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Active, not recruiting NCT01841450 Phase 4
30 Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination Completed NCT00941096 Phase 4 Bimatoprost and Bimatoprost/Timolol fixed combination.
31 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed NCT00330577 Phase 4 timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
32 A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma Recruiting NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
33 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study Active, not recruiting NCT03323164 Phase 4 Timolol Maleate;Brimonidine Tartrate
34 Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients Completed NCT03104621 Phase 4 Benzalkonium chloride (BAK);0.0015% tafluprost
35 Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension Completed NCT03395535 Phase 4 Primary Medical Treatment Pathway
36 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
37 A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness Completed NCT03204487 Phase 4 Tafluprost 15µg/ml
38 Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension. Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)
39 24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost Completed NCT00444184 Phase 4 Travoprost/timolol fixed combination, travoprost
40 Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs Completed NCT00675207 Phase 4 Brimonidine purite 0.15%;Dorzolamide 2%;Brinzolamide 1%
41 Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension Completed NCT00300079 Phase 4 brinzolamide 1.0%
42 Comparison Of Trabeculectomy Versus The Ex-PRESS Miniature Glaucoma Device In The Same Patient: A Prospective Randomized Study Completed NCT00698438 Phase 4
43 Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive Medication Active, not recruiting NCT02868190 Phase 4
44 Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents Active, not recruiting NCT02873806 Phase 4 Topical travoprost;Tobramycin;Dexamethasone
45 Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy Completed NCT01263444 Phase 4 Brinzolamide 1% / timolol 0.5% Fixed Combination;Habitual prostaglandin monotherapy
46 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost Completed NCT01443988 Phase 4 Travoprost
47 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Active, not recruiting NCT01444040 Phase 4 Travoprost
48 Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America Completed NCT01518244 Phase 4 Brinzolamide/timolol maleate fixed combination
49 Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil Terminated NCT01514734 Phase 4 Brinzolamide/timolol maleate fixed combination
50 Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma Completed NCT01471158 Phase 4 Brinzolamide/Timolol Maleate Fixed Combination (AZARGA);Dorzolamide/timolol Maleate Fixed Combination (COSOPT)

Search NIH Clinical Center for Glaucoma, Primary Open Angle

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Glaucoma, Primary Open Angle cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Glaucoma, Primary Open Angle:
Renexus� (NT-501), CNTF-secreting cells for treatment of retinal diseases
Embryonic/Adult Cultured Cells Related to Glaucoma, Primary Open Angle:
Human retinal stem cells secreting CNTF PMIDs: 16805711 17508034 16505355 23049090 15684670 12581701 15223826 18830926

Genetic Tests for Glaucoma, Primary Open Angle

Genetic tests related to Glaucoma, Primary Open Angle:

# Genetic test Affiliating Genes
1 Primary Open Angle Glaucoma 29 OPTN
2 Primary Open Angle Glaucoma (adult Onset) 29
3 Glaucoma 1, Open Angle, E 29

Anatomical Context for Glaucoma, Primary Open Angle

MalaCards organs/tissues related to Glaucoma, Primary Open Angle:

41
Eye, Testes, Endothelial, Brain, Cortex, Bone, Retina
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Glaucoma, Primary Open Angle:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Ganglion Cell Layer Mature Ganglion Cells Affected by disease

Publications for Glaucoma, Primary Open Angle

Articles related to Glaucoma, Primary Open Angle:

(show top 50) (show all 1548)
# Title Authors Year
1
Association of catalase polymorphisms with primary open-angle glaucoma in a Chinese population. ( 28829657 )
2018
2
Systemic Medication Associations with Presumed Advanced or Uncontrolled Primary Open-Angle Glaucoma. ( 29433851 )
2018
3
Are we ready for genetic testing for primary open-angle glaucoma? ( 29379103 )
2018
4
The Efficacy of Transcorneal Electrical Stimulation for the Treatment of Primary Open-angle Glaucoma: A Pilot Study. ( 29415904 )
2018
5
Proteomic Analysis of Aqueous Humor from Primary Open Angle Glaucoma Patients on Drug Treatment Revealed Altered Complement Activation Cascade. ( 29901396 )
2018
6
Alzheimer's disease and primary open-angle glaucoma associated with vascular health in patients of African descent. ( 29855159 )
2018
7
Carbohydrate ingestion induces differential autonomic dysregulation in normal-tension glaucoma and primary open angle glaucoma. ( 29879162 )
2018
8
A new diagnostic model of primary open angle glaucoma based on FD-OCT parameters. ( 29977806 )
2018
9
Discontinuation of the herbal preparation <i>Hypericum perforatum</i>, also known as St John's wort, associated with improved intraocular pressure control in a patient on topical beta-blockers for primary open-angle glaucoma. ( 29930462 )
2018
10
Correction to: The Effect of Posture on Intraocular Pressure and Systemic Hemodynamic Parameters in Treated and Untreated Patients with Primary Open-Angle Glaucoma, by Katsanos, A., Dastiridou, A.I., Quaranta, L., Rulli, E., Riva, I., Dimasi, V., Tsironi, E.E., and Weinreb, R.N. J Ocul Pharmacol Ther 2017;33(8):598-603. DOI: 10.1089/jop.2017.0030. ( 29393727 )
2018
11
A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study. ( 29945799 )
2018
12
Progression of Primary Open Angle Glaucoma in Diabetic and Non-diabetic Patients. ( 29447914 )
2018
13
The effect of trabeculectomy on serum brain-derived neurotrophic factor levels in primary open-angle glaucoma. ( 29417213 )
2018
14
Reduced Cerebral Blood Flow in the Visual Cortex and Its Correlation with Glaucomatous Structural Damage to the Retina in Patients with Mild to Moderate Primary Open Angle Glaucoma. ( 29952821 )
2018
15
Comparison of total/active ghrelin levels in primary open angle glaucoma, pseudoexfoliation glaucoma and pseudoexfoliation syndrome. ( 29862183 )
2018
16
Selective laser trabeculoplasty for primary open-angle glaucoma patients younger than 40 years. ( 29426447 )
2018
17
The relationship between HDAC6, CXCR3, and SIRT1 genes expression levels with progression of primary open-angle glaucoma. ( 29384425 )
2018
18
Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension. ( 29873009 )
2018
19
Simplifying &amp;quot;target&amp;quot; intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. ( 29582808 )
2018
20
Identification and genotype phenotype correlation of novel mutations in SIX6 gene in primary open angle glaucoma. ( 29405792 )
2018
21
Reduction of Intraocular Pressure by Additional Trabeculotomy Ab Externo in Eyes with Primary Open-angle Glaucoma. ( 29916998 )
2018
22
Genome-wide association study identifies seven novel susceptibility loci for primary open-angle glaucoma. ( 29452408 )
2018
23
Comparison of optical coherence tomography findings and visual field changes in patients with primary open-angle glaucoma and amyotrophic lateral sclerosis. ( 29169899 )
2018
24
Differentially expressed microRNAs in the aqueous humor of patients with exfoliation glaucoma or primary open-angle glaucoma. ( 29401312 )
2018
25
Noninvasive Detection of Mitochondrial Dysfunction in Ocular Hypertension and Primary Open-angle Glaucoma. ( 29750714 )
2018
26
Differentiating Occult Branch Retinal Artery Occlusion from Primary Open-angle Glaucoma. ( 29370018 )
2018
27
The risk of primary open angle glaucoma following vitreoretinal surgery- a population-based study. ( 29940165 )
2018
28
Pattern of peripapillary capillary density loss in ischemic optic neuropathy compared to that in primary open-angle glaucoma. ( 29320503 )
2018
29
Factors associated with developing a fear of falling in subjects with primary open-angle glaucoma. ( 29433472 )
2018
30
Screening for Primary Open-angle Glaucoma (POAG). ( 29870406 )
2018
31
Baseline Lamina Cribrosa Curvature and Subsequent Visual Field Progression Rate in Primary Open-Angle Glaucoma. ( 29945800 )
2018
32
A multiethnic genome-wide association study of primary open-angle glaucoma identifies novel risk loci. ( 29891935 )
2018
33
CO2 Laser-assisted Deep Sclerectomy Combined With Phacoemulsification in Patients With Primary Open-angle Glaucoma and Cataract. ( 30113508 )
2018
34
Brain-Derived Neurotrophic Factor in Patients with Primary Open-Angle Glaucoma and Age-related Cataract. ( 29120253 )
2018
35
Evaluation of a Trabecular Microbypass Stent With Cataract Extraction in Severe Primary Open-angle Glaucoma. ( 29194199 )
2018
36
Optic nerve head morphology in primary open-angle glaucoma and nonarteritic anterior ischaemic optic neuropathy measured with spectral domain optical coherence tomography. ( 30240137 )
2018
37
Anterior Segment Optical Coherence Tomography Analysis of Iris Morphometric Changes Induced by Prostaglandin Analogues Treatment in Patients with Primary Open Angle Glaucoma or Ocular Hypertension. ( 30123376 )
2018
38
Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. ( 30234748 )
2018
39
The assessment of structural changes on optic nerve head and macula in primary open angle glaucoma and ocular hypertension. ( 30364206 )
2018
40
Diffusion Tensor Imaging Detects Microstructural Differences of Visual Pathway in Patients With Primary Open-Angle Glaucoma and Ocular Hypertension. ( 30459581 )
2018
41
Optic disc microvasculature dropout in primary open-angle glaucoma measured with optical coherence tomography angiography. ( 30086177 )
2018
42
Inner Retinal Changes in Primary Open-Angle Glaucoma Revealed Through Adaptive Optics-Optical Coherence Tomography. ( 30095607 )
2018
43
Bone Lead Levels and Risk of Incident Primary Open-Angle Glaucoma: The VA Normative Aging Study. ( 30102601 )
2018
44
Blood Pressure and Heart Rate Variability in Primary Open-Angle Glaucoma and Normal Tension Glaucoma. ( 30110187 )
2018
45
Predictors of Outcome in Selective Laser Trabeculoplasty: A Long-term Observation Study in Primary Angle-closure Glaucoma After Laser Peripheral Iridotomy Compared With Primary Open-angle Glaucoma. ( 30113512 )
2018
46
Concordance of 24-h intraocular pressure curve in patients with untreated unilateral primary open-angle glaucoma. ( 30116395 )
2018
47
Analysis of CYP1B1 sequence alterations in patients with primary open-angle glaucoma of Saudi origin. ( 30127590 )
2018
48
Peripapillary Vessel Density in Glaucomatous Eyes: Comparison Between Pseudoexfoliation Glaucoma and Primary Open-angle Glaucoma. ( 30134370 )
2018
49
Intraocular retinal thickness asymmetry in early stage of primary open angle glaucoma and normal tension glaucoma. ( 30140639 )
2018
50
MicroRNA-related polymorphisms in pseudoexfoliation syndrome, pseudoexfoliative glaucoma, and primary open-angle glaucoma. ( 30148417 )
2018

Variations for Glaucoma, Primary Open Angle

UniProtKB/Swiss-Prot genetic disease variations for Glaucoma, Primary Open Angle:

75
# Symbol AA change Variation ID SNP ID
1 OPTN p.His26Asp VAR_021537 rs200710076
2 OPTN p.Glu50Lys VAR_021538 rs28939688
3 OPTN p.Glu103Asp VAR_021540 rs134686580
4 OPTN p.His486Arg VAR_021546 rs373425395

ClinVar genetic disease variations for Glaucoma, Primary Open Angle:

6 (show top 50) (show all 436)
# Gene Variation Type Significance SNP ID Assembly Location
1 WDR36 NM_139281.2(WDR36): c.1973A> G (p.Asp658Gly) single nucleotide variant Likely benign rs34595252 GRCh37 Chromosome 5, 110454719: 110454719
2 WDR36 NM_139281.2(WDR36): c.1973A> G (p.Asp658Gly) single nucleotide variant Likely benign rs34595252 GRCh38 Chromosome 5, 111119021: 111119021
3 WDR36 NM_139281.2(WDR36): c.1345G> A (p.Ala449Thr) single nucleotide variant Likely benign rs35703638 GRCh37 Chromosome 5, 110441839: 110441839
4 WDR36 NM_139281.2(WDR36): c.1345G> A (p.Ala449Thr) single nucleotide variant Likely benign rs35703638 GRCh38 Chromosome 5, 111106140: 111106140
5 WDR36 NM_139281.2(WDR36): c.1586G> A (p.Arg529Gln) single nucleotide variant Likely benign rs116529882 GRCh37 Chromosome 5, 110445979: 110445979
6 WDR36 NM_139281.2(WDR36): c.1586G> A (p.Arg529Gln) single nucleotide variant Likely benign rs116529882 GRCh38 Chromosome 5, 111110280: 111110280
7 OPTN NM_001008211.1(OPTN): c.148G> A (p.Glu50Lys) single nucleotide variant Pathogenic rs28939688 GRCh37 Chromosome 10, 13151270: 13151270
8 OPTN NM_001008211.1(OPTN): c.148G> A (p.Glu50Lys) single nucleotide variant Pathogenic rs28939688 GRCh38 Chromosome 10, 13109270: 13109270
9 OPTN OPTN, 2-BP INS, 691AG insertion Pathogenic
10 OPTN NM_001008211.1(OPTN): c.1634G> A (p.Arg545Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs75654767 GRCh37 Chromosome 10, 13178766: 13178766
11 OPTN NM_001008211.1(OPTN): c.1634G> A (p.Arg545Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs75654767 GRCh38 Chromosome 10, 13136766: 13136766
12 OPTN NM_001008211.1(OPTN): c.293T> A (p.Met98Lys) single nucleotide variant Benign rs11258194 GRCh37 Chromosome 10, 13152400: 13152400
13 OPTN NM_001008211.1(OPTN): c.293T> A (p.Met98Lys) single nucleotide variant Benign rs11258194 GRCh38 Chromosome 10, 13110400: 13110400
14 CYP1B1 NM_000104.3(CYP1B1): c.241T> A (p.Tyr81Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs9282671 GRCh37 Chromosome 2, 38302291: 38302291
15 CYP1B1 NM_000104.3(CYP1B1): c.241T> A (p.Tyr81Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs9282671 GRCh38 Chromosome 2, 38075148: 38075148
16 MYOC NM_000261.1(MYOC): c.1102C> T (p.Gln368Ter) single nucleotide variant Likely pathogenic rs74315329 GRCh37 Chromosome 1, 171605478: 171605478
17 MYOC NM_000261.1(MYOC): c.1102C> T (p.Gln368Ter) single nucleotide variant Likely pathogenic rs74315329 GRCh38 Chromosome 1, 171636338: 171636338
18 OPTN NM_001008211.1(OPTN): c.102G> A (p.Thr34=) single nucleotide variant Benign rs2234968 GRCh37 Chromosome 10, 13151224: 13151224
19 OPTN NM_001008211.1(OPTN): c.102G> A (p.Thr34=) single nucleotide variant Benign rs2234968 GRCh38 Chromosome 10, 13109224: 13109224
20 OPTN NM_021980.4(OPTN): c.123G> A (p.Leu41=) single nucleotide variant Benign/Likely benign rs11591687 GRCh37 Chromosome 10, 13151245: 13151245
21 OPTN NM_021980.4(OPTN): c.123G> A (p.Leu41=) single nucleotide variant Benign/Likely benign rs11591687 GRCh38 Chromosome 10, 13109245: 13109245
22 LTBP2 NM_000428.2(LTBP2): c.1484G> A (p.Arg495Gln) single nucleotide variant Likely pathogenic rs137854858 GRCh37 Chromosome 14, 75017969: 75017969
23 LTBP2 NM_000428.2(LTBP2): c.1484G> A (p.Arg495Gln) single nucleotide variant Likely pathogenic rs137854858 GRCh38 Chromosome 14, 74551266: 74551266
24 LTBP2 NM_000428.2(LTBP2): c.3571G> A (p.Glu1191Lys) single nucleotide variant Uncertain significance rs137854862 GRCh37 Chromosome 14, 74975388: 74975388
25 LTBP2 NM_000428.2(LTBP2): c.3571G> A (p.Glu1191Lys) single nucleotide variant Uncertain significance rs137854862 GRCh38 Chromosome 14, 74508685: 74508685
26 LTBP2 NM_000428.2(LTBP2): c.4250A> G (p.Gln1417Arg) single nucleotide variant Likely pathogenic rs137854863 GRCh37 Chromosome 14, 74971805: 74971805
27 LTBP2 NM_000428.2(LTBP2): c.4250A> G (p.Gln1417Arg) single nucleotide variant Likely pathogenic rs137854863 GRCh38 Chromosome 14, 74505102: 74505102
28 LTBP2 NM_000428.2(LTBP2): c.4356G> A (p.Pro1452=) single nucleotide variant Uncertain significance rs137854865 GRCh37 Chromosome 14, 74971699: 74971699
29 LTBP2 NM_000428.2(LTBP2): c.4356G> A (p.Pro1452=) single nucleotide variant Uncertain significance rs137854865 GRCh38 Chromosome 14, 74504996: 74504996
30 LTBP2 NM_000428.2(LTBP2): c.4668G> C (p.Pro1556=) single nucleotide variant Uncertain significance rs137854866 GRCh37 Chromosome 14, 74970224: 74970224
31 LTBP2 NM_000428.2(LTBP2): c.4668G> C (p.Pro1556=) single nucleotide variant Uncertain significance rs137854866 GRCh38 Chromosome 14, 74503521: 74503521
32 LTBP2 NM_000428.2(LTBP2): c.4912G> A (p.Val1638Met) single nucleotide variant Likely pathogenic rs137854860 GRCh37 Chromosome 14, 74969614: 74969614
33 LTBP2 NM_000428.2(LTBP2): c.4912G> A (p.Val1638Met) single nucleotide variant Likely pathogenic rs137854860 GRCh38 Chromosome 14, 74502911: 74502911
34 MYOC NM_000261.1(MYOC): c.227G> A (p.Arg76Lys) single nucleotide variant Benign/Likely benign rs2234926 GRCh37 Chromosome 1, 171621525: 171621525
35 MYOC NM_000261.1(MYOC): c.227G> A (p.Arg76Lys) single nucleotide variant Benign/Likely benign rs2234926 GRCh38 Chromosome 1, 171652385: 171652385
36 MYOC NM_000261.1(MYOC): c.855G> T (p.Thr285=) single nucleotide variant Benign/Likely benign rs146606638 GRCh37 Chromosome 1, 171605725: 171605725
37 MYOC NM_000261.1(MYOC): c.855G> T (p.Thr285=) single nucleotide variant Benign/Likely benign rs146606638 GRCh38 Chromosome 1, 171636585: 171636585
38 OPTN NM_001008211.1(OPTN): c.553-5C> T single nucleotide variant Benign rs2244380 GRCh37 Chromosome 10, 13158262: 13158262
39 OPTN NM_001008211.1(OPTN): c.553-5C> T single nucleotide variant Benign rs2244380 GRCh38 Chromosome 10, 13116262: 13116262
40 CARD10 NM_014550.3(CARD10): c.2485C> T (p.Arg829Trp) single nucleotide variant risk factor rs201794655 GRCh37 Chromosome 22, 37888801: 37888801
41 CARD10 NM_014550.3(CARD10): c.2485C> T (p.Arg829Trp) single nucleotide variant risk factor rs201794655 GRCh38 Chromosome 22, 37492794: 37492794
42 CARD10 NM_014550.3(CARD10): c.1210C> T (p.Arg404Trp) single nucleotide variant risk factor rs750643216 GRCh37 Chromosome 22, 37902372: 37902372
43 CARD10 NM_014550.3(CARD10): c.1210C> T (p.Arg404Trp) single nucleotide variant risk factor rs750643216 GRCh38 Chromosome 22, 37506365: 37506365
44 CARD10 NM_014550.3(CARD10): c.1024G> A (p.Val342Met) single nucleotide variant risk factor rs200148764 GRCh37 Chromosome 22, 37904575: 37904575
45 CARD10 NM_014550.3(CARD10): c.1024G> A (p.Val342Met) single nucleotide variant risk factor rs200148764 GRCh38 Chromosome 22, 37508568: 37508568
46 CARD10 NM_014550.3(CARD10): c.983C> T (p.Ala328Val) single nucleotide variant risk factor rs139006752 GRCh37 Chromosome 22, 37904616: 37904616
47 CARD10 NM_014550.3(CARD10): c.983C> T (p.Ala328Val) single nucleotide variant risk factor rs139006752 GRCh38 Chromosome 22, 37508609: 37508609
48 CARD10 NM_014550.3(CARD10): c.635G> A (p.Arg212His) single nucleotide variant risk factor rs1057519378 GRCh38 Chromosome 22, 37516037: 37516037
49 CARD10 NM_014550.3(CARD10): c.635G> A (p.Arg212His) single nucleotide variant risk factor rs1057519378 GRCh37 Chromosome 22, 37912044: 37912044
50 MYOC NM_000261.1(MYOC): c.1111T> C (p.Tyr371His) single nucleotide variant Pathogenic rs878854408 GRCh37 Chromosome 1, 171605469: 171605469

Expression for Glaucoma, Primary Open Angle

Search GEO for disease gene expression data for Glaucoma, Primary Open Angle.

Pathways for Glaucoma, Primary Open Angle

Pathways related to Glaucoma, Primary Open Angle according to KEGG:

37
# Name Kegg Source Accession
1 Ribosome biogenesis in eukaryotes hsa03008

Pathways related to Glaucoma, Primary Open Angle according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.66 ELN LOXL1 TGFB2

GO Terms for Glaucoma, Primary Open Angle

Cellular components related to Glaucoma, Primary Open Angle according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.26 COCH ELN LOXL1 MYOC
2 collagen-containing extracellular matrix GO:0062023 8.92 COCH ELN LOXL1 TGFB2

Biological processes related to Glaucoma, Primary Open Angle according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neural retina development GO:0003407 8.96 ATOH7 TGFB2
2 visual perception GO:0007601 8.92 ABCA4 CYP1B1 SIX6 WDR36

Sources for Glaucoma, Primary Open Angle

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....